Kuala lumpur: Malaysia must move beyond being merely a recipient or a conduit of external innovation by shaping its own unique footprint on the global map of medical discovery, says Health Minister Datuk Seri Dr Dzulkefly Ahmad. He emphasized the importance of empowering human capital, intensifying and expanding collaborative networks, and strengthening a sustainable and competitive ecosystem across all aspects of research to place Malaysia on the global map of medical discovery.
According to BERNAMA News Agency, Dr Dzulkefly Ahmad highlighted the transition from being a consumer of science to becoming a global contributor as integral to Malaysia’s journey towards becoming a Global Trusted Research Nation. He underscored the necessity of strengthening site resources by improving facilities, operational systems, and essential research support like study coordinators, stating that strong infrastructure is foundational to scientific integrity.
During his speech at the launch of the 5th Annual Clinical Research Malaysia (CRM) Trial Connect Conference 2026, Dzulkefly noted the presence of over 3,200 skilled professionals powering Malaysia’s current clinical research ecosystem. He acknowledged the appointment of 30 percent new principal investigators in Malaysia’s Roll of Honour last year as a sign of successful succession planning and robust institutional support.
Dzulkefly also stressed the importance of collaboration in building a resilient and world-class clinical research ecosystem, especially amid geopolitical uncertainties. He praised CRM’s significant contributions to the country’s Gross National Income (GNI) and its role in creating high-value jobs annually.
The conference, themed ‘The Rise of Asia in Clinical Trials,’ attracted over 1,100 attendees from more than 150 organizations across 20 countries, including clinical research leaders, international organizations, and national agencies throughout Southeast Asia and the broader Asian region.
Additionally, Dzulkefly launched the latest edition of Malaysia’s Good Clinical Practice Guidelines during the ceremony, reaffirming the nation’s commitment to upholding international standards and ensuring the highest quality in clinical trial conduct.